GlassScriptPhysician profile
Kevin T Lavery
NPI 1629073036
$8,669.07
in general payments reported to CMS, 2019-2025
13 companies · $1,426 in 2025
The $1,426 reported for 2025 was more than what 84% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,524 · 2020: $2,822 · 2021: $254 · 2022: $2,120 · 2023: $313 · 2024: $211 · 2025: $1,426.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,326 · Food and Beverage: $624.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,325.57 |
| Food and Beverage | $623.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $3,612.85 | 2019-2025 | Clareon, Unity, Wavelight Refractive Suite |
| Ivantis, INC | $2,552.25 | 2020-2021 | |
| Carl Zeiss Meditec USA, INC. | $1,716.89 | 2022 | |
| Allergan, INC. | $203.71 | 2019-2021 | |
| Johnson & Johnson Surgical Vision, INC. | $190.24 | 2024 | Catalys System, Tecnis Iol |
| Hologic Sales and Service, LLC | $116.78 | 2020 | |
| Glaukos Corporation | $96.53 | 2019-2025 | Istent Infinite, Idosetr |
| Novartis Pharmaceuticals Corporation | $57.51 | 2019-2021 | |
| The Cameron-Ehlen Group, INC. | $35.91 | 2019 | |
| Rxsight INC | $28.33 | 2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $21.26 | 2019 | |
| Kala Pharmaceuticals, INC. | $20.95 | 2021 | |
| Sun Pharmaceutical Industries INC. | $15.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Lavery listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.